New Zealand has been chosen to be part of a late-stage trial for a new European Covid-19 vaccine. The VLA2001 vaccine, created by company French biotech company Valneva, has already been trailed on approximately 4-thousand volunteers in Europe. They are now looking for 300 adults across New Zealand. The participants must be older than 56 and not have previously had Covid-19 or received a Covid vaccine. Our reporter Ella Stewart spoke with Director of Southern Clinical Trials Christchurch Dr Simon Carson who is the lead coordinating investigator for the New Zealand trial.